Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- QUBT +14.7%, NIU +6.4%, YSG +4.7%, SOHU +4.7%, HIVE +1.8%, BRC +1.3%,
Other news:
- ZYME +35% (HERIZON-GEA-01 Phase 3 Results)
- RPTX +24.2% (enters into definitive agreement to be acquired by XenoTherapeutics)
- JAZZ +21.1% (reports HERIZON-GEA-01 Phase 3 results supporting Ziihera)
- SSP +19.3% (Sinclair (SBGI) acquired the Class A Common Stock in contemplation of a possible combination; discloses 8.2% active stake)
- AVR +9.8% (presents data from 100 DurAVR THV patients at PCR london valves)
- TNXP +9.5% (TONMYATM is now commercially available at pharmacies by prescription in the United States)
- ESLT +8.3% (inks $2.3 bln international contract)
- FIGR +5.1% (new Soros stake)
- GOOGL +4.4% (new Berkshire Hathaway stake)
- COCO +3.8% (comments on tariff relief impact)
- QLGN +3.7% (shareholders approve full transition to AIxCrypto Holdings, Advancing AI × Web3 Strategy)
- SE +3.3% (authorizes share buyback program)
- SRDX +3% (FTC does not intend to appeal denial of injunction, order preventing closing set to expire today)
- ONC +2.7% (reports Phase 3 results support ZIIHERA as HER2-Targeted Therapy-of-Choice and combination with TEVIMBRA and Chemotherapy as new Standard of Care in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma)
- MASI +2.6% (wins $634 mln jury verdict against Apple (AAPL) for patent infringement)
- NUVL +2.6% (topline pivotal data from ALKOVE-1 Clinical Trial of Neladalkib)
- INDV +2.2% (new Soros stake)
- MNRO +2% (new Icahn stake)
- FUN +2% (new Jana Partners stake)
- OGN +2% (Organon and Henlius secure FDA approval for POHERDY)
- DNN +2% (expands strategic perimeter around Wheeler River through Multi-JV Deal with Skyharbour)
- JBIO +1.9% (files for 16,125,269 share common stock offering by selling shareholders)
- WALD +1.6% (sold its rights to the "Obagi" trademark in Japan to Rohto Pharma; Obagi Medical shares new clinical data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting)
- BILL +1.1% (new Starboard stake)